에피제네틱스 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Epigenetics Market Size, Share & Trends Analysis Report By Product (Reagents, Kits, Instruments), By Technology (DNA Methylation), By Application (Oncology), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,404,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,816,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,641,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

에피제네틱스 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 에피제네틱스 시장 규모는 2024-2030년에 15.3%의 CAGR을 기록하며, 2030년까지 391억 5,000만 달러에 달할 것으로 예측되고 있습니다.

이 시장은 에피제네틱스 연구개발을 위한 자금 조달, 투자 및 규제 승인 증가, 신약 개발에서 에피제네틱스적 효소의 사용 확대, 게놈 시퀀싱 비용 감소 등의 요인에 의해 주도되고 있습니다. 에피제네틱스는 종양 이외의 분야에서도 유익한 용도를 입증하고 있으며, 상업적 확장이 예상됩니다. 분자 수준에서 에피제네틱스적 변화에 대한 이해에 대한 수요 증가와 약물 치료의 발전은 아마도 이러한 조직들이 R&D 프로그램을 지원하게 될 것입니다.

또한 역학 및 유전체 연구 프로그램(EGRP)과 같은 구상은 종양의 발생과 결과를 더 잘 이해하기 위한 연구 노력에 인센티브를 제공합니다. 시장 상승을 주도하는 조직으로는 국제 인간 후성유전체 컨소시엄(IHEC), 미국 국립종양연구소(NCI), 미국 국립보건원(NIH) 등이 있습니다. 이들 기관은 에피제네틱스 분야의 제품 개발 및 연구개발을 포함한 구상에 자금을 지원하고 지원하고 있습니다. 예를 들어 미국 국립보건원(NIH)은 공동기금 에피제네틱스 프로그램을 통해 전 세계에서 최첨단 에피제네틱스 연구를 활발히 추진하고 있습니다.

에피제네틱스 시장 보고서 하이라이트

• 제품별로는 시약 부문이 2023년 전 세계 매출의 33.45%를 차지하며 업계를 주도했습니다. 이 부문의 큰 점유율은 에피제네틱스 연구에서 시약의 높은 사용률에 기인합니다.
• 기술별로는 DNA 메틸화 부문이 2023년 매출 점유율 45.36%로 시장을 장악했습니다. 에피제네틱스에서 DNA 메틸화에 대한 수요는 유전자 발현 조절에 있으며, 매우 중요한 역할을 하기 때문입니다.
• 용도별로는 종양이 2023년 69.06%의 매출 점유율로 시장을 장악했습니다. 종양의 에피제네틱스에 대한 수요는 에피제네틱스적 변화와 암 발생 사이의 복잡한 관계에서 비롯됩니다.
• 북미가 2023년 38.19%의 점유율로 시장을 장악했습니다. 이 지역은 일반 대중의 인식이 높아지고, 의료 시설이 잘 갖추어져 있으며, R&D 투자가 활발하게 이루어지고 있으며, 성장세를 보이고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 에피제네틱스 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/보조적인 시장 전망.
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
  • 시장 기회 분석
• 에피제네틱스 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 에피제네틱스 시장 : 제품 추정·동향 분석

• 부문 대시보드
• 세계의 에피제네틱스 시장의 제품의 동향 분석
• 세계의 에피제네틱스 시장 규모·동향 분석, 제품별, 2018-2030년
• 시약
• 키트
• 기기
• 효소
• 서비스

제5장 에피제네틱스 시장 : 기술 추정·동향 분석

• 부문 대시보드
• 세계의 에피제네틱스 시장의 기술의 동향 분석
• 세계의 에피제네틱스 시장 규모·동향 분석, 기술별, 2018-2030년
• DNA 메틸화
• 히스톤 메틸화
• 히스톤 아세틸화
• 대형 논코딩 RNA
• 마이크로 RNA 수식
• 크로마틴 구조

제6장 에피제네틱스 시장 : 용도 추정·동향 분석

• 부문 대시보드
• 세계의 에피제네틱스 시장의 용도의 동향 분석
• 세계의 에피제네틱스 시장 규모·동향 분석, 용도별, 2018-2030년
• 종양
• 비종양

제7장 에피제네틱스 시장 : 최종 용도 추정·동향 분석

• 부문 대시보드
• 세계의 에피제네틱스 시장의 최종 용도의 동향 분석
• 세계의 에피제네틱스 시장 규모·동향 분석, 최종 용도별, 2018-2030년
• 학술연구
• 임상 연구
• 병원·클리닉
• 제약·바이오테크놀러지 기업
• 기타

제8장 에피제네틱스 시장 : 지역 추정·동향 분석

• 지역의 시장 점유율 분석, 2023년·2030년
• 지역의 시장 대시보드
• 시장 규모와 예측·동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 기업/경쟁 분류
• 전략 매핑
• 기업 시장 현황 분석, 2023년
• 기업 개요/상장기업
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Eisai Co., Ltd.
  • Novartis AG
  • ELEMENT BIOSCIENCES.
  • Dovetail Genomics.
  • Illumina, Inc.
  • Promega Corporation
  • Abcam plc

KSA

영문 목차

영문목차

Epigenetics Market Growth & Trends:

The global epigenetics market size is expected to reach USD 39.15 billion by 2030, registering a CAGR of 15.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is being driven by factors, such as the rise in funding, investment & regulatory approvals for epigenetics research & development, the expansion of the use of epigenetic enzymes in drug discovery & development, and the decreasing cost of genome sequencing. Since epigenetics has demonstrated beneficial applications outside of cancer, commercial expansion is envisaged.The rising demand for understanding epigenetic alterations at the molecular level, as well as the advancement of medicinal treatments, would likely push these organizations to support research and development programs.

Furthermore, initiatives, such as the Epidemiology and Genomics Research Program (EGRP), provide incentives for research efforts aimed at better-comprehending cancer genesis and consequences.A few organizations that help fuel the market's rise are the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH). These organizations support funding and help for initiatives involving product development and R&D in the field of epigenetics. For instance, the National Institutes of Health aggressively promotes cutting-edge epigenetic research worldwide through its common fund epigenomics program.

Epigenetics Market Report Highlights:

• By product, the reagents segment dominated the industry, accounting for 33.45% of the global revenue in 2023. The large share of this segment can be attributed to the high usage of reagents in epigenetic research studies.
• By technology, the DNA methylation segment dominated the market with a revenue share of 45.36% in 2023. DNA methylation's demand in epigenetics stems from its pivotal role in gene expression regulation.
• By application, the oncology segment dominated the market with a revenue share of 69.06% in 2023. Oncology's demand for epigenetics arises from the intricate relationship between epigenetic alterations and cancer development.
• North America dominated the market and accounted for a 38.19% share in 2023. The region experiences growth due to heightened public awareness, robust medical facilities, and substantial R&D investments.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective - 1
  • 1.10.2. Objective - 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Epigenetics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Rising geriatric patient population
    • 3.2.1.3. Increasing government initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of standardization in epigenetics-based diagnostics
    • 3.2.2.2. Lack of skilled professionals
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Improving healthcare infrastructure in developing economies
• 3.3. Epigenetics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Epigenetics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Epigenetics Market Product Movement Analysis
• 4.3. Global Epigenetics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagents
  • 4.4.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Kits
  • 4.5.1. Kits market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. ChIP sequencing Kit
    • 4.5.2.1. ChIP sequencing kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Whole Genomic Amplification Kit
    • 4.5.3.1. Whole genomic amplification kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Bisulfite Conversion Kit
    • 4.5.4.1. Bisulfite conversion kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. RNA sequencing Kit
    • 4.5.5.1. RNA sequencing kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Instruments
  • 4.6.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Enzymes market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Services
  • 4.8.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Epigenetics Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Epigenetics Market Technology Movement Analysis
• 5.3. Global Epigenetics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. DNA Methylation
  • 5.4.1. DNA methylation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Histone Methylation
  • 5.5.1. Histone methylation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Histone Acetylation
  • 5.6.1. Histone Acetylation Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Large non-coding RNA
  • 5.7.1. Large non-coding RNA market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MicroRNA modification
  • 5.8.1. MicroRNA modification market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Chromatin structures
  • 5.9.1. Chromatin structures market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Epigenetics Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Epigenetics Market Application Movement Analysis
• 6.3. Global Epigenetics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Solid tumors
    • 6.4.2.1. Solid tumors market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Liquid tumors
    • 6.4.3.1. Liquid tumors market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non-oncology
  • 6.5.1. Non-oncology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Inflammatory diseases
    • 6.5.2.1. Inflammatory diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Metabolic diseases
    • 6.5.3.1. Metabolic diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Infectious diseases
    • 6.5.4.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Cardiovascular diseases
    • 6.5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Others
    • 6.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Epigenetics Market: End-use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Epigenetics Market End-use Movement Analysis
• 7.3. Global Epigenetics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 7.4. Academic Research
  • 7.4.1. Academic research market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinical Research
  • 7.5.1. Clinical research market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Hospitals & Clinics
  • 7.6.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other Users
  • 7.8.1. Other users market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Epigenetics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.4. North America
  • 8.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Target disease prevalence
    • 8.4.2.4. Competitive scenario
    • 8.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Target disease prevalence
    • 8.4.3.4. Competitive scenario
    • 8.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Target disease prevalence
    • 8.5.2.4. Competitive scenario
    • 8.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Target disease prevalence
    • 8.5.3.4. Competitive scenario
    • 8.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Target disease prevalence
    • 8.5.4.4. Competitive scenario
    • 8.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Target disease prevalence
    • 8.5.5.4. Competitive scenario
    • 8.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Target disease prevalence
    • 8.5.6.4. Competitive scenario
    • 8.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Target disease prevalence
    • 8.5.7.4. Competitive scenario
    • 8.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Target disease prevalence
    • 8.5.8.3. Regulatory framework
    • 8.5.8.4. Competitive scenario
    • 8.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.9. Denmark
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Regulatory framework
    • 8.5.9.3. Target disease prevalence
    • 8.5.9.4. Competitive scenario
    • 8.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Target disease prevalence
    • 8.6.2.4. Competitive scenario
    • 8.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Target disease prevalence
    • 8.6.3.4. Competitive scenario
    • 8.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Target disease prevalence
    • 8.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Target disease prevalence
    • 8.6.5.4. Competitive scenario
    • 8.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Target disease prevalence
    • 8.6.6.4. Competitive scenario
    • 8.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Target disease prevalence
    • 8.6.7.3. Regulatory framework
    • 8.6.7.4. Competitive scenario
    • 8.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Target disease prevalence
    • 8.7.2.4. Competitive scenario
    • 8.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. Mexico
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Target disease prevalence
    • 8.7.3.4. Competitive scenario
    • 8.7.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Argentina
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Target disease prevalence
    • 8.7.4.4. Competitive scenario
    • 8.7.4.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Target disease prevalence
    • 8.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Target disease prevalence
    • 8.8.3.4. Competitive scenario
    • 8.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework
    • 8.8.4.3. Target disease prevalence
    • 8.8.4.4. Competitive scenario
    • 8.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Regulatory framework
    • 8.8.5.3. Target disease prevalence
    • 8.8.5.4. Competitive scenario
    • 8.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Company Profiles/Listing
  • 9.4.1. F. Hoffmann-La Roche Ltd
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Eisai Co., Ltd.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Novartis AG
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. ELEMENT BIOSCIENCES.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Dovetail Genomics.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Illumina, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Promega Corporation
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Abcam plc
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives

관련자료